Bicycle Therapeutics plc

WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
CUSIP
088786108
SEDOL
BKDQKM6
CIK
0001761612
www.bicycletherapeutics.com
LEI:
©
FIGI: BBG00P0YWPK6
BCYC
Bicycle Therapeutics plc
GICS: - · Sektor: Healthcare · Sub-Sektor: Biotechnology
AI
PROFILER
NAME
Bicycle Therapeutics plc
ISIN
US0887861088
TICKER
BCYC
MIC
XNAS
REUTERS
BCYC.OQ
BLOOMBERG
BCYC US
BUILD THEMEFOLIO IDEEN TEILEN DISKUTIEREN
HEBEL INVESTIEREN
GIF DE 728x90
Financial Intelligence
360° iHub Crowd ATH Tracker Index Tracker ETF TF Spicy X-Billboard
FÜR INVESTOREN
FÜR TRADER
Börsenhandel Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Fr., 03.01.2025       Bicycle Therapeutics
US0887861088

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on January 2, 2025, the Compensation Committee of the company’s Board of Directors granted to 12 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 67,300 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Induceme...
weiterlesen
Bicycle Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Fr., 13.12.2024       Bicycle Therapeutics
US0887861088

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in breast cancer patients with NECTIN4 ge...
weiterlesen
Bicycle Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Di., 10.12.2024       Bicycle Therapeutics
US0887861088

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of three new distinguished global oncology experts to its Clinical Advisory Board (CAB) to support the advancement of the compan...
weiterlesen
Bicycle Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Mo., 02.12.2024       Bicycle Therapeutics
US0887861088

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on December 2, 2024, the Compensation Committee of the company’s Board of Directors granted to thirteen new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 62,400 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 I...
weiterlesen
Bicycle Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Mo., 25.11.2024       Bicycle Therapeutics
US0887861088

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data showing the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cance...
weiterlesen
Bicycle Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Di., 12.11.2024       Bicycle Therapeutics
US0887861088

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Nov. 19, 2024, at 10:30 a.m. GMT. A live ...
weiterlesen
Bicycle Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Fr., 01.11.2024       Bicycle Therapeutics
US0887861088

Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on November 1, 2024, the Compensation Committee of the company’s Board of Directors granted to twelve new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 56,700 ordinary shares. These awards were made under Bicycle Therapeutics’ 2024 Ind...
weiterlesen
Bicycle Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Do., 31.10.2024       Bicycle Therapeutics
US0887861088

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the third quarter ended September 30, 2024. “In the third quarter, we continued to make signi...
weiterlesen
Bicycle Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Mi., 23.10.2024       Bicycle Therapeutics
US0887861088

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the presentation of the first human imaging data validating the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrat...
weiterlesen
Bicycle Therapeutics
Research & Analysen Termsheet Terminal
Permalink
Mi., 16.10.2024       Bicycle Therapeutics
US0887861088

Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present data highlighting its potential to develop differentiated radiopharmaceutical molecules, called Bicycle Radionucli...
weiterlesen
Bicycle Therapeutics
Research & Analysen Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Informationen zu Product Placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S